Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Analgesia, new research approaches.

M Morre, R Boigegrain, R Roncucci

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie

|January 1, 1982

Summary

Researchers explored novel pain relievers by reviewing enkephalinase inhibition and the potential of kappa receptors for pain management without severe side effects like respiratory depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice.

Infection and immunity·2015

Same author

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Same author

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2012

Same author

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

The Journal of pharmacology and experimental therapeutics·1999

Same author

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

The Journal of pharmacology and experimental therapeutics·1999

Area of Science:

Pharmacology
Neuroscience
Medicinal Chemistry

Background:

The pursuit of centrally acting analgesics with reduced side effects is a significant challenge in pain management research.
Existing analgesics, particularly opioids, are associated with dose-limiting adverse effects such as respiratory depression, tolerance, and dependence.

Purpose of the Study:

To review the concept of enkephalinase inhibition as a strategy for developing new analgesics.
To discuss the potential of kappa receptors as a target for analgesia with a favorable side effect profile.

Main Methods:

Review of scientific literature and symposia discussions on enkephalinase inhibition.
Exploration of the role and characteristics of kappa opiate receptors in pain pathways.

Main Results:

Enkephalinase inhibition presents a potential mechanism for analgesic development by preventing the breakdown of endogenous enkephalins.
Evidence suggests that kappa receptor stimulation may offer pain relief without inducing significant respiratory depression and with limited tolerance and dependence.

Conclusions:

Enkephalinase inhibition is a promising avenue for developing novel analgesics with improved safety profiles.
Targeting kappa receptors represents a viable strategy for achieving analgesia with reduced adverse effects compared to traditional opioids.

Related Experiment Videos